Companies looking to bring the first CAR-T treatment for autoimmune diseases to market will present their latest data at the European Alliance of Associations for Rheumatology (EULAR) meeting this week.
Biotechs Vie To Take The Lead In Autoimmune CAR-Ts
First clinical efficacy readouts from several biotech companies developing CAR-Ts for systemic lupus erythematosus will be unveiled at EULAR, though the level of competition may be unsustainable.
